One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The original QTc phrase >15% of baseline is ambiguous and is preserved rather than silently converted to a current-label algorithm. This excerpt alone is not the complete monitored initiation protocol.
Initiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks.
What to reconcile: Apply only to the stated formulation, indication and renal population.
Open this note and its source referencesInitiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks.
| Calculated CrCl (mL/min) | Initial oral regimen |
|---|---|
| >60 | 500 mcg twice daily |
| 40-60 | 250 mcg twice daily |
| 20 to <40 | 125 mcg twice daily |
| <20 | Contraindicated |
Initial oral doses by calculated CrCl are 500 mcg twice daily above 60, 250 mcg twice daily at 40-60, and 125 mcg twice daily at 20 to below 40 mL/min. Below 20, use is contraindicated. Initiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks.
RDM74-tikosyn-official-1 · Source locator: Renal guidance: Dosage and Administration, individualized dose initiation steps 1-7
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=dofetilide&s1=RDM74-tikosyn-official&h1=c7d371f439777fcf9262a57aa9d018198f4dc5bf33040eb06877afb5b20b7d37